Endo says it “absolutely remains open to trying to find a constructive resolution and settlement” ahead of its impending patent-litigation showdown with Eagle Pharmaceuticals and Amneal Pharmaceuticals over Endo’s $700m Vasostrict (vasopressin) injectable.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?